Skip to main content
Erschienen in: Journal of Cardiovascular Translational Research 3/2019

23.10.2018 | Original Article

Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure

verfasst von: Rosa M. Agra-Bermejo, Rocio Gonzalez-Ferreiro, J. Nicolos Lopez-Canoa, Alfonso Varela-Roman, Ines Gomez-Otero, Sonia Eiras, José R. González-Juanatey

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

A obesity paradox has been described following heart failure (HF). The aim of this study was to analyze the association between food intake-involved adipokines and long-term weight changes. Leptin, adiponectin, and omentin were analyzed in 92 acute HF (AHF) patients at discharge, classified on the basis of weight gains or losses > 6%. The mean follow-up was 256 ± 143 days. Leptin and adiponectin levels were similar among weight groups. However, omentin levels were higher in those patients who had gained weight (16 ± 5 ng/mL) than in those who had lost weight (12 ± 4 ng/mL) or showed no weight change (11 ± 5 ng/mL; p < 0.002). Omentin levels were the best independent predictors for patients with weight gain, who had less mortality and hospital readmission during the follow-up. The association between omentin levels and weight gain might explain part of the obesity paradox in HF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 67, 968–977.CrossRef Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 67, 968–977.CrossRef
2.
Zurück zum Zitat Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., Woo, M. A., & Tillisch, J. H. (2001). The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology, 38, 789–795.CrossRefPubMed Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., Woo, M. A., & Tillisch, J. H. (2001). The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology, 38, 789–795.CrossRefPubMed
3.
Zurück zum Zitat Oreopoulos, A., Padwal, R., Kalantar-Zadeh, K., Fonarow, G. C., Norris, C. M., & McAlister, F. A. (2008). Body mass index and mortality in heart failure: A meta-analysis. American Heart Journal, 156, 13–22.CrossRefPubMed Oreopoulos, A., Padwal, R., Kalantar-Zadeh, K., Fonarow, G. C., Norris, C. M., & McAlister, F. A. (2008). Body mass index and mortality in heart failure: A meta-analysis. American Heart Journal, 156, 13–22.CrossRefPubMed
4.
Zurück zum Zitat Uretsky, S., Messerli, F. H., Bangalore, S., et al. (2007). Obesity paradox in patients with hypertension and coronary artery disease. The American Journal of Medicine, 120, 863–870.CrossRefPubMed Uretsky, S., Messerli, F. H., Bangalore, S., et al. (2007). Obesity paradox in patients with hypertension and coronary artery disease. The American Journal of Medicine, 120, 863–870.CrossRefPubMed
5.
Zurück zum Zitat Gonzalez-Cambeiro, M. C., Abu-Assi, E., Raposeiras-Roubin, S., et al. (2014). Exploring the obesity paradox in atrial fibrillation. AFBAR (atrial fibrillation Barbanza area) registry results. Journal of Atrial Fibrillation, 6, 991.PubMedPubMedCentral Gonzalez-Cambeiro, M. C., Abu-Assi, E., Raposeiras-Roubin, S., et al. (2014). Exploring the obesity paradox in atrial fibrillation. AFBAR (atrial fibrillation Barbanza area) registry results. Journal of Atrial Fibrillation, 6, 991.PubMedPubMedCentral
6.
Zurück zum Zitat Farre, N., Aranyo, J., Enjuanes, C., et al. (2015). Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: The role of sympathetic activation. International Journal of Cardiology, 181, 120–126.CrossRefPubMed Farre, N., Aranyo, J., Enjuanes, C., et al. (2015). Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: The role of sympathetic activation. International Journal of Cardiology, 181, 120–126.CrossRefPubMed
7.
Zurück zum Zitat Lavie, C. J., De Schutter, A., Alpert, M. A., Mehra, M. R., Milani, R. V., & Ventura, H. O. (2014). Obesity paradox, cachexia, frailty, and heart failure. Heart Failure Clinics, 10, 319–326.CrossRefPubMed Lavie, C. J., De Schutter, A., Alpert, M. A., Mehra, M. R., Milani, R. V., & Ventura, H. O. (2014). Obesity paradox, cachexia, frailty, and heart failure. Heart Failure Clinics, 10, 319–326.CrossRefPubMed
8.
Zurück zum Zitat Nagarajan, V., Kohan, L., Holland, E., Keeley, E. C., & Mazimba, S. (2016). Obesity paradox in heart failure: A heavy matter. ESC Heart Failure, 3, 227–234.CrossRefPubMedPubMedCentral Nagarajan, V., Kohan, L., Holland, E., Keeley, E. C., & Mazimba, S. (2016). Obesity paradox in heart failure: A heavy matter. ESC Heart Failure, 3, 227–234.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Sandek, A., Anker, S. D., & von Haehling, S. (2009). The gut and intestinal bacteria in chronic heart failure. Current Drug Metabolism, 10, 22–28.CrossRefPubMed Sandek, A., Anker, S. D., & von Haehling, S. (2009). The gut and intestinal bacteria in chronic heart failure. Current Drug Metabolism, 10, 22–28.CrossRefPubMed
10.
Zurück zum Zitat Khalid, U., Ather, S., Bavishi, C., et al. (2014). Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol, 64, 2743–2749.CrossRefPubMedPubMedCentral Khalid, U., Ather, S., Bavishi, C., et al. (2014). Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol, 64, 2743–2749.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Friedman, J. (2015). Leptin and the regulation of food intake and body weight. Journal of Nutritional Science and Vitaminology (Tokyo), 61(Suppl), S202.CrossRef Friedman, J. (2015). Leptin and the regulation of food intake and body weight. Journal of Nutritional Science and Vitaminology (Tokyo), 61(Suppl), S202.CrossRef
12.
Zurück zum Zitat Brunetti, L., Orlando, G., Ferrante, C., et al. (2013). Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides, 44, 66–74.CrossRefPubMed Brunetti, L., Orlando, G., Ferrante, C., et al. (2013). Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides, 44, 66–74.CrossRefPubMed
13.
Zurück zum Zitat Kubota, N., Yano, W., Kubota, T., et al. (2007). Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism, 6, 55–68.CrossRefPubMed Kubota, N., Yano, W., Kubota, T., et al. (2007). Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism, 6, 55–68.CrossRefPubMed
14.
Zurück zum Zitat Fernandez-Trasancos, A., Agra, R. M., Garcia-Acuna, J. M., Fernandez, A. L., Gonzalez-Juanatey, J. R., & Eiras, S. (2017). Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring), 25, 1042–1049.CrossRef Fernandez-Trasancos, A., Agra, R. M., Garcia-Acuna, J. M., Fernandez, A. L., Gonzalez-Juanatey, J. R., & Eiras, S. (2017). Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring), 25, 1042–1049.CrossRef
15.
Zurück zum Zitat Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical Research Communications, 323, 630–635.CrossRefPubMed Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical Research Communications, 323, 630–635.CrossRefPubMed
16.
Zurück zum Zitat Sun, Y., Yang, Y., Qin, Z., et al. (2016). The acute-phase protein Orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway. Diabetes, 65, 1630–1641.CrossRefPubMed Sun, Y., Yang, Y., Qin, Z., et al. (2016). The acute-phase protein Orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway. Diabetes, 65, 1630–1641.CrossRefPubMed
17.
Zurück zum Zitat Agra, R. M., Fernandez-Trasancos, A., Diaz-Rodriguez, E., et al. (2018). Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: Impact in de novo heart failure patients. International Journal of Medical Sciences, 15, 417–424.CrossRefPubMedPubMedCentral Agra, R. M., Fernandez-Trasancos, A., Diaz-Rodriguez, E., et al. (2018). Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: Impact in de novo heart failure patients. International Journal of Medical Sciences, 15, 417–424.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ponikowski, P., Voors, A. A., Anker, S. D., et al. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. European Heart Journal, 37, 2129–2200.CrossRefPubMed Ponikowski, P., Voors, A. A., Anker, S. D., et al. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. European Heart Journal, 37, 2129–2200.CrossRefPubMed
19.
Zurück zum Zitat Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine, 130, 461–470.CrossRefPubMed Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine, 130, 461–470.CrossRefPubMed
20.
Zurück zum Zitat Anker, S. D., Negassa, A., Coats, A. J., et al. (2003). Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet, 361, 1077–1083.CrossRefPubMed Anker, S. D., Negassa, A., Coats, A. J., et al. (2003). Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet, 361, 1077–1083.CrossRefPubMed
21.
Zurück zum Zitat Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N. G., et al. (2005). CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutrición Hospitalaria, 20, 38–45.PubMed Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N. G., et al. (2005). CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutrición Hospitalaria, 20, 38–45.PubMed
22.
Zurück zum Zitat Kouris, N. T., Zacharos, I. D., Kontogianni, D. D., et al. (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. European Journal of Heart Failure, 7, 199–203.CrossRefPubMed Kouris, N. T., Zacharos, I. D., Kontogianni, D. D., et al. (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. European Journal of Heart Failure, 7, 199–203.CrossRefPubMed
23.
Zurück zum Zitat Littnerova, S., Parenica, J., Spinar, J., et al. (2015). Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS One, 10, e0117142.CrossRefPubMedPubMedCentral Littnerova, S., Parenica, J., Spinar, J., et al. (2015). Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS One, 10, e0117142.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 128, 1810–1852.CrossRef Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 128, 1810–1852.CrossRef
25.
Zurück zum Zitat McMurray, J. J., Adamopoulos, S., Anker, S. D., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. European Journal of Heart Failure, 14, 803–869.CrossRefPubMed McMurray, J. J., Adamopoulos, S., Anker, S. D., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. European Journal of Heart Failure, 14, 803–869.CrossRefPubMed
26.
Zurück zum Zitat Pocock, S. J., McMurray, J. J., Dobson, J., et al. (2008). Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29, 2641–2650.CrossRefPubMed Pocock, S. J., McMurray, J. J., Dobson, J., et al. (2008). Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29, 2641–2650.CrossRefPubMed
28.
Zurück zum Zitat Beck-da-Silva, L., Higginson, L., Fraser, M., Williams, K., & Haddad, H. (2005). Effect of orlistat in obese patients with heart failure: A pilot study. Congestive Heart Failure, 11, 118–123.CrossRefPubMed Beck-da-Silva, L., Higginson, L., Fraser, M., Williams, K., & Haddad, H. (2005). Effect of orlistat in obese patients with heart failure: A pilot study. Congestive Heart Failure, 11, 118–123.CrossRefPubMed
29.
Zurück zum Zitat Mariotti, R., Castrogiovanni, F., Canale, M. L., Borelli, G., & Rondinini, L. (2008). Weight loss and quality of life in chronic heart failure patients. Journal of Cardiovascular Medicine (Hagerstown, Md.), 9, 576–580.CrossRef Mariotti, R., Castrogiovanni, F., Canale, M. L., Borelli, G., & Rondinini, L. (2008). Weight loss and quality of life in chronic heart failure patients. Journal of Cardiovascular Medicine (Hagerstown, Md.), 9, 576–580.CrossRef
30.
Zurück zum Zitat Alpert, M. A., Terry, B. E., Mulekar, M., et al. (1997). Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. The American Journal of Cardiology, 80, 736–740.CrossRefPubMed Alpert, M. A., Terry, B. E., Mulekar, M., et al. (1997). Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. The American Journal of Cardiology, 80, 736–740.CrossRefPubMed
31.
Zurück zum Zitat Zamora, E., Diez-Lopez, C., Lupon, J., et al. (2016). Weight loss in obese patients with heart failure. Journal of the American Heart Association, 5, e002468.CrossRefPubMedPubMedCentral Zamora, E., Diez-Lopez, C., Lupon, J., et al. (2016). Weight loss in obese patients with heart failure. Journal of the American Heart Association, 5, e002468.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Rossignol, P., Masson, S., Barlera, S., et al. (2015). Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure, 17, 424–433.CrossRefPubMed Rossignol, P., Masson, S., Barlera, S., et al. (2015). Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure, 17, 424–433.CrossRefPubMed
33.
Zurück zum Zitat Lavie, C. J., Sharma, A., Alpert, M. A., et al. (2016). Update on obesity and obesity paradox in heart failure. Progress in Cardiovascular Diseases, 58, 393–400.CrossRefPubMed Lavie, C. J., Sharma, A., Alpert, M. A., et al. (2016). Update on obesity and obesity paradox in heart failure. Progress in Cardiovascular Diseases, 58, 393–400.CrossRefPubMed
34.
Zurück zum Zitat Sharma, A., Lavie, C. J., Borer, J. S., et al. (2015). Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. The American Journal of Cardiology, 115, 1428–1434.CrossRefPubMed Sharma, A., Lavie, C. J., Borer, J. S., et al. (2015). Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. The American Journal of Cardiology, 115, 1428–1434.CrossRefPubMed
35.
Zurück zum Zitat Ambrosy, A. P., Cerbin, L. P., Armstrong, P. W., et al. (2017). Body weight change during and after hospitalization for acute heart failure: Patient characteristics, markers of congestion, and outcomes: Findings from the ASCEND-HF trial. JACC Heart Failure, 5, 1–13.CrossRefPubMedPubMedCentral Ambrosy, A. P., Cerbin, L. P., Armstrong, P. W., et al. (2017). Body weight change during and after hospitalization for acute heart failure: Patient characteristics, markers of congestion, and outcomes: Findings from the ASCEND-HF trial. JACC Heart Failure, 5, 1–13.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Nunez, J., Nunez, E., Consuegra, L., et al. (2007). Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart, 93, 716–721.CrossRefPubMed Nunez, J., Nunez, E., Consuegra, L., et al. (2007). Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure? Heart, 93, 716–721.CrossRefPubMed
37.
Zurück zum Zitat Nunez, J., Sanchis, J., Bodi, V., et al. (2010). Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. European Heart Journal, 31, 1752–1763.CrossRefPubMed Nunez, J., Sanchis, J., Bodi, V., et al. (2010). Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. European Heart Journal, 31, 1752–1763.CrossRefPubMed
38.
Zurück zum Zitat Kovacic, D., Marinsek, M., Gobec, L., Lainscak, M., & Podbregar, M. (2008). Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clinical Research in Cardiology, 97, 24–31.CrossRefPubMed Kovacic, D., Marinsek, M., Gobec, L., Lainscak, M., & Podbregar, M. (2008). Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clinical Research in Cardiology, 97, 24–31.CrossRefPubMed
39.
Zurück zum Zitat Barbosa-Ferreira, J. M., Fernandes, F., Dabarian, A., & Mady, C. (2013). Leptin in heart failure. Expert Opin Med Diagn, 7, 113–117.CrossRefPubMed Barbosa-Ferreira, J. M., Fernandes, F., Dabarian, A., & Mady, C. (2013). Leptin in heart failure. Expert Opin Med Diagn, 7, 113–117.CrossRefPubMed
40.
Zurück zum Zitat Szabo, T., Scherbakov, N., Sandek, A., et al. (2013). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis, 24, 50–56.CrossRefPubMed Szabo, T., Scherbakov, N., Sandek, A., et al. (2013). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis, 24, 50–56.CrossRefPubMed
41.
Zurück zum Zitat de Souza Batista, C. M., Yang, R. Z., Lee, M. J., et al. (2007). Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 1655–1661.CrossRefPubMed de Souza Batista, C. M., Yang, R. Z., Lee, M. J., et al. (2007). Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 1655–1661.CrossRefPubMed
42.
Zurück zum Zitat Lafontan, M., & Viguerie, N. (2006). Role of adipokines in the control of energy metabolism: Focus on adiponectin. Current Opinion in Pharmacology, 6, 580–585.CrossRefPubMed Lafontan, M., & Viguerie, N. (2006). Role of adipokines in the control of energy metabolism: Focus on adiponectin. Current Opinion in Pharmacology, 6, 580–585.CrossRefPubMed
43.
Zurück zum Zitat Agra, R. M., Teijeira-Fernandez, E., Pascual-Figal, D., et al. (2014). Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. European Journal of Clinical Investigation, 44, 29–37.CrossRefPubMed Agra, R. M., Teijeira-Fernandez, E., Pascual-Figal, D., et al. (2014). Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. European Journal of Clinical Investigation, 44, 29–37.CrossRefPubMed
44.
Zurück zum Zitat Eiras, S., Varela-Roman, A., Andrade, M. C., et al. (2017). Non classical monocytes levels, increased by subcutaneous fat-Secretome, are associated with less Rehospitalization after heart failure admission. Journal of Cardiovascular Translational Research, 10, 16–26.CrossRefPubMed Eiras, S., Varela-Roman, A., Andrade, M. C., et al. (2017). Non classical monocytes levels, increased by subcutaneous fat-Secretome, are associated with less Rehospitalization after heart failure admission. Journal of Cardiovascular Translational Research, 10, 16–26.CrossRefPubMed
45.
Zurück zum Zitat Watanabe, T., Watanabe-Kominato, K., Takahashi, Y., Kojima, M., & Watanabe, R. (2017). Adipose tissue-derived Omentin-1 function and regulation. Comprehensive Physiology, 7, 765–781.CrossRefPubMed Watanabe, T., Watanabe-Kominato, K., Takahashi, Y., Kojima, M., & Watanabe, R. (2017). Adipose tissue-derived Omentin-1 function and regulation. Comprehensive Physiology, 7, 765–781.CrossRefPubMed
46.
Zurück zum Zitat von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009). Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics, 121, 227–252.CrossRef von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009). Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics, 121, 227–252.CrossRef
47.
Zurück zum Zitat Ostman, J., Efendic, S., & Arner, P. (1969). Catecholamines and metabolism of human adipose tissue. I. Comparison between in vitro effects of noradrenaline, adrenaline and theophylline on lipolysis in omental adipose tissue. Acta Medica Scandinavica, 186, 241–246.CrossRefPubMed Ostman, J., Efendic, S., & Arner, P. (1969). Catecholamines and metabolism of human adipose tissue. I. Comparison between in vitro effects of noradrenaline, adrenaline and theophylline on lipolysis in omental adipose tissue. Acta Medica Scandinavica, 186, 241–246.CrossRefPubMed
48.
Zurück zum Zitat Wedick, N. M., Mayer-Davis, E. J., Wingard, D. L., Addy, C. L., & Barrett-Connor, E. (2001). Insulin resistance precedes weight loss in adults without diabetes : The rancho Bernardo study. American Journal of Epidemiology, 153, 1199–1205.CrossRefPubMed Wedick, N. M., Mayer-Davis, E. J., Wingard, D. L., Addy, C. L., & Barrett-Connor, E. (2001). Insulin resistance precedes weight loss in adults without diabetes : The rancho Bernardo study. American Journal of Epidemiology, 153, 1199–1205.CrossRefPubMed
49.
Zurück zum Zitat Uriel, N., Gonzalez-Costello, J., Mignatti, A., et al. (2014). Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Failure, 1, 331–337.CrossRef Uriel, N., Gonzalez-Costello, J., Mignatti, A., et al. (2014). Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Failure, 1, 331–337.CrossRef
Metadaten
Titel
Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure
verfasst von
Rosa M. Agra-Bermejo
Rocio Gonzalez-Ferreiro
J. Nicolos Lopez-Canoa
Alfonso Varela-Roman
Ines Gomez-Otero
Sonia Eiras
José R. González-Juanatey
Publikationsdatum
23.10.2018
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 3/2019
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9840-y

Weitere Artikel der Ausgabe 3/2019

Journal of Cardiovascular Translational Research 3/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.